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Summary The prevalence of atrial ﬁbrillation is steadily increasing throughout the world
because of ageing populations and better management of coronary heart disease. An inter-
national literature review was conducted to estimate the prevalence and incidence of atrial
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ﬁbrillation in France. A review of the literature on comorbidities was also performed. Finally,
French mortality and hospitalization data were analysed using the PMSI database. The preva-
lence of atrial ﬁbrillation is estimated to be between 600,000 and 1 million people; of these,
two-thirds are aged > 75 years. The incidence is estimated at between 110,000 and 230,000
new cases per year. In 2008, 412,000 hospitalized patients had a diagnosis of atrial ﬁbrillation;
this ﬁgure increased by 26% in the 3-year period between 2005 and 2008. These ﬁndings high-
light the importance of targeting therapy, of upstream therapy, and of therapy that provides
clear clinical and economic advantages over the well-established reductions already achieved
in atrial ﬁbrillation morbidity, mortality and cost. In addition, new prevention strategies should
be developed, particularly secondary prevention strategies in patients with cardiovascular
diseases.
© 2011 Elsevier Masson SAS. All rights reserved.
MOTS CLÉS
Fibrillation atriale ;
Épidémiologie ;
Prévalence ;
Incidence ;
Comorbidités ;
Hospitalisation
Résumé La ﬁbrillation atriale (FA) est en augmentation constante dans le monde, du fait du
vieillissement des populations et de la meilleure prise en charge de la pathologie coronaire.
Une revue de littérature internationale a été réalisée pour estimer la prévalence et l’incidence
de la FA en France. Une analyse des publications sur les comorbidités a également été réal-
isée, ainsi qu’une analyse des données franc¸aises de mortalité et d’hospitalisations (PMSI). La
prévalence de la FA est estimée entre 600 000 et unmillion de personnes, dont deux tiers de
plus de 75 ans et l’incidence est estimée entre 110 000 et 230 000 nouveaux cas par an. En 2008,
412 000 patients hospitalisés ont eu un diagnostic de FA. Ce chiffre a augmenté de 26% sur
les trois années 2005—2008. Ces données soulignent l’importance de la prévention des mal-
adies cardiovasculaires et du développement de thérapies ciblant la FA, avec des avantages
clairement établis en termes d’efﬁcacité clinique et de rapport bénéﬁce/risque, ainsi que le
développement de stratégies de prévention secondaire chez les patients porteurs de maladie
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bbreviations
F atrial ﬁbrillation
HF congestive heart failure
I conﬁdence interval
YHA New York Heart Association
MSI Programme for the Medicalization of Information
Systems
ackground
F is the most common arrhythmia and is characterized by
ncontrolled atrial activation and a subsequent deteriora-
ion of atrial mechanical function. Stroke and CHF are the
ost common complications in subjects with AF [1], and
ssociated mortality rates are higher than in patients with-
ut AF [1—3].
Epidemiological surveys show that the risk of AF increases
ith age, particularly during the sixth and seventh decades
f life [1,4—6]. The increase in prevalence of AF over the
ast 50 years, due to the growing elderly population in indus-
rialized countries, reﬂects this trend [6—8]. The projected
ontinued increase in the prevalence of AF is a cause of great
oncern, as this disease presents a major public health and
ocioeconomic burden [9—11]. Targeting preventive health-
are and treatment for patients who are at risk is becoming
n increasingly attractive option in order to reduce morbid-
ty and control medical costs.
o
A
e
ss droits réservés.
In this report, we carried out a systematic review of
he literature to gather data on the prevalence and con-
equences of AF. Extrapolation of these data to French
opulation statistics should enable us to better deﬁne the
ublic health repercussions of AF in France and to identify
peciﬁc target populations for monitoring and treatment.
he incidence and prevalence of AF are not well known in
rance. A study by Guize et al. was published in 2007, but
he study population was not representative of the general
opulation [12].
ethods
iterature review
literature review of published epidemiological studies
n the ﬁeld of AF was conducted using PubMed, with the
ollowing terms: ‘atrial ﬁbrillation’ and ‘epidemiology’ or
prevalence’ or ‘incidence’ or ‘mortality’ or ‘comorbidity’.
his literature review took into account only general pop-
lation or community-based studies, which relate to the
ampling of a geographical territory or of an administrative
atabase, such as the Health Maintenance Organization in
he USA or the General Practitioner database in the UK or
ther European countries. These studies cover all types of
F and the distinction between different types of AF is gen-
rally not detailed in the published articles or in the data
ources.
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Table 1 Prevalence of atrial ﬁbrillation in large,
population-based surveys.
Study
Meta-analysis of four USA studies [4]
Number of persons 14,000
Prevalence of atrial ﬁbrillation (%)
Overall 0.89
≥ 40 years 2.3
≥ 65 years 5.9
Median age (years) 75
Atrial ﬁbrillation in California 1996—1997
(ATRIA study) [5]
Number of persons 17,974
Prevalence of atrial ﬁbrillation (%)
Overall (≥ 20 years) 0.95
20—55 years 0.1
≥ 60 years 3.8
≥ 80 years 9.0
Median age (years) 71.2
ECG baseline study (Rotterdam study)
[25]
Number of persons 6808
Prevalence of atrial ﬁbrillation (%)
Overall (≥ 55 years) 5.5
55—59 years 0.7
≥ 85 years 17.8
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Statistics
Data from international studies were used to extrapolate
incidence and prevalence rates in the French population:
the prevalence or incidence rates by age observed in the
different studies were applied to the French population
structure.
Analysis of French hospitalization data
Since 1991, public and private hospitals have been required
to evaluate and analyse their activities. This analysis
is based on the systematic collecting and computerized
processing of minimal standardized medicoadministrative
information contained in the standardized discharge case
records, in a medicoeconomic database called PMSI.
The standardized discharge case record contains a lim-
ited amount of mandatory information: diagnoses (principal
diagnosis and associated diagnosis) according to the Inter-
national Classiﬁcation of Diseases (ICD-10), procedures,
related complications and/or morbidities and other infor-
mation such as length of stay, patient’s age, etc.
An analysis of the PMSI database records for 2005—2008
was conducted for patients hospitalized for AF (as the prin-
cipal or associated diagnosis).
Classiﬁcation of atrial ﬁbrillation
Several different classiﬁcations of AF can be found in the lit-
erature, complicating interstudy group comparisons [10,13].
The following classiﬁcation, dividing AF into one of four
types based on the number and duration of episodes, is
recommended by the current guidelines of the American
College of Cardiology, the American Heart Association and
the European Society of Cardiology [10]: ﬁrst detected
episode of AF (symptomatic or asymptomatic); paroxysmal
(self-terminating) AF, when an episode lasts ≤ 7 days and
usually < 24 hours; persistent AF, when an episode lasts > 7
days, usually requiring termination by electrical or pharma-
cological cardioversion; permanent AF (previously referred
to as chronic AF [13]), when AF fails to stop after cardiover-
sion, or cardioversion is not attempted [10]. Paroxysmal and
persistent AF may both be recurrent (two or more episodes)
and are often progressive. Approximately 8—9% of patients
with paroxysmal AF progress to permanent AF within 1 year
and 25% within 5 years [14]. Higher rates of progression
are observed in patients with persistent AF, with approx-
imately 40% developing permanent AF by the end of the
1-year period [15].
The classiﬁcations have been deﬁned for clinical
research; they are very detailed and based on clinical fea-
tures, so they are difﬁcult to use in epidemiological studies.
Results
Prevalence of atrial ﬁbrillation: international
data
The prevalence of AF increases with age in both men and
women (Table 1) and approximately 70% of patients with
AF are aged 65—85 years [4]. In the general population
i
t
a
0
aECG: electrocardiogram.
ged > 60 years, the prevalence of AF is estimated to be
elow 1% [4,5,16]. However, a meta-analysis of four large
opulation-based surveys [17—20] carried out in the USA,
estern Australia and Europe revealed that the prevalence
f AF doubles with each decade of life after the age of
0 years, increasing to around 10% in individuals aged > 80
ears [4]. In another long-term, follow-up study of 3983
ale aircrew recruits, the probability of developing AF over
44-year follow-up period was 7.5% [3]. These observa-
ions are supported by surveys conducted in the UK [21] and
cotland [22,23]. Murphy et al. recorded a prevalence of
.4/1000 persons in men and 7.9/1000 in women, increasing
o 71/1000 in subjects aged > 85 years [22] (Fig. 1).
A higher age-adjusted prevalence of AF has been doc-
mented consistently in men compared with in women
4,5,17—19,24,25]. The age-adjusted risk of developing AF
s also signiﬁcantly higher in Caucasians than in Africans
5,21,26].
Asymptomatic AF has been reported in 11—32% of
atients in different studies [12,27,28] and seems to bemore
ommon in white (92% vs 88%, P = 0.01), male (77% vs 59%,
< 0.0001) patients.
The prevalence of AF has increased signiﬁcantly over the
ast 50 years. Between 1968 and 1970, the prevalence of AF
n US men aged 65—84 years was reported to be 3.2%, but
his increased to 9.1% in the same age group between 1987
nd 1989 [1]. A similar increase in the prevalence of AF, from
.84 to 1.49% in men, and from 0.83 to 1.29% in women, was
lso observed in the UK between 1994 and 2003 [7].
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to 3.68 (95% CI 3.42—3.95) in 2000 [29]. Poisson regressionigure 1. Prevalence of atrial ﬁbrillation according to age in dif-
erent studies. M: men; W: women.
revalence of atrial ﬁbrillation in France
study carried out in the 1990s (ALFA) attempted to
haracterize the different subsets of AF observed by gen-
ral cardiologists in ofﬁce practice in France. The relative
revalences of paroxysmal, chronic and recent onset AF
mong 756 patients with electrocardiogram-conﬁrmed AF
ere 22.1, 51.4 and 26.4%, respectively [13]. Patients with
hronic AF were signiﬁcantly older (P < 0.0002) than those
ith paroxysmal AF but there was no association between
ex and type of AF [13]. Asymptomatic AF was present in
1.4% of patients.
The current prevalence of AF in France was recently
stimated by Guize et al. in a study population comprising
w
i
(
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Table 2 Age-related incidence of atrial ﬁbrillation in differen
years).
Framingham study [24] Cardiovascular Health
study [26]
Age
(years)
Incidence of
AF
Age
(years)
Incidence of
AF
Men Women Men Women
55—64 3.1 1.9
65—75 9.0 5.5 65—69 12.3 10.9
70—74 22.8 9.1
75—84 17.5 15.0 75—79 34.8 23.1
≥ 80 58.7 25.1
85—94 38.0 31.4
Total Total 26.4 14.1
Combined
total
19.2
AF: atrial ﬁbrillation.A. Charlemagne et al.
8,961 men and 55,109 women, who had a free check-up in
he Centre d’Investigations Préventives et Cliniques, Paris
12]. AF was identiﬁed in 0.05% of men and 0.01% of women
ged < 50 years, compared with in 6.5% of men and 5.2% of
omen aged > 80 years.
By applying the prevalence ﬁgures calculated for the
ifferent age groups and sexes in the USA, Australia and
urope [4,5,25] to the French population, we estimated that
here are currently between 600,000 and 1 million peo-
le in France with AF, that two-thirds of these subjects
re likely to be aged > 75 years and that most of them will
e women.
ncidence of atrial ﬁbrillation: international
ata
he incidence of AF is also higher in older subjects
Table 2) [3,24—26]. The incidence of AF has been reported
o double for every 10-year increment in age, with an
nnual incidence of 3.1 cases per 1000 patient-examinations
n men and 1.9 cases in women aged 55—64 years,
ncreasing to 38.0 and 31.4 cases, respectively, in elderly
atients aged 85—94 years [24]. Mabo et al. also reported
higher annual incidence in older subjects, increasing
rom 0.1% in those aged < 40 years to more than 1.5%
n women and more than 2% in men aged > 80 years
16].
The incidence of AF has also increased over the past 30
ears [16]. Miyasaka et al., in the Minnesota study, showed
n age- and sex-adjusted incidence of AF per 1000 person-
ears of 3.04 (95% CI 2.78—3.31) in 1980, which increasedith adjustment for age and sex conﬁrmed an increase in the
ncidence over the 21-year period of 12.6% (95%CI 2.1—23.1)
P = 0.014). The incidence ratio for men/women was 1.86
P < 0.01) [29].
t studies (calculated as number of cases per 1000 patient-
Manitoba follow-up study
[3]
Rotterdam study [25]
Age
(years)
Incidence of
AF
Age
(years)
Incidence of
AF
Men & women Men Women
< 50 0.5
50—54 0.8
55—59 2.2 55—59 2.6
60—64 3.6 60—64 4.9 2.1
65—69 5.0 65—69 6.6 4.7
≥ 70 9.7 70—74 12.4 10.1
75—79 19.9 11.5
80—84 25.5 18.2
≥ 85 16.9 ≥ 85 25.4 15.2
Total 2.0 Total 11.5 8.9
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Estimated incidence of atrial ﬁbrillation in
France
The current incidence of AF in France is unknown, but by
applying the above incidence rates to French population ﬁg-
ures, it is estimated that there are between 110,000 and
230,000 new cases of AF per year in France. This represents
a signiﬁcant burden for the healthcare service.
Comorbidities and risk factors for atrial
ﬁbrillation
Underlying heart disease is present in 70% of patients with
AF, and a number of speciﬁc predictors have been identiﬁed,
including ischaemic heart disease, valvular (mitral) disease,
CHF, hypertension, cardiomyopathy, supraventricular and
ventricular rhythm disturbances [1,3,10]. The prevalence of
AF increases in line with the severity of heart disease (NYHA
I prevalence 4% vs NYHA IV prevalence 50%) [10].
In the Framingham 38-year study, 20.6% of men who
developed AF had CHF at inclusion, compared with only
3.2% without AF (26% vs 2.9% of women) [24]. In this study,
patients with CHF (odds ratio 4.5 [95% CI 3.1—6.6] in men
and 5.9 [4.2—8.4] in women) and valvular heart disease
(odds ratio 1.8 [95% CI 1.2—2.5] in men and 3.4 [2.5—4.5]
in women) had a particularly high risk of developing AF. The
2—3 year incidence of AF in heart failure patients has been
reported to be 5—10% [30].
Patients with asymptomatic AF are more likely to have
less severe heart disease and a lower incidence of coro-
nary artery disease (28% vs 40%, P < 0.0001), CHF (13% vs
24%, P < 0.0001) and peripheral vascular disease (4% vs 7%,
p = 0.018) [27]. Conversely, the prevalence of symptomatic
AF increases with the severity of these conditions.
Hypertension (odds ratio 1.5 [95% CI 1.2—2.0] in men
and 1.4 [1.1—1.8] in women) and myocardial infarction in
men (odds ratio 1.4 [95% CI 1.0—2.0]) also increase the
risk of AF (Table 3) [24]. According to the different stud-
ies related to AF comorbidities, 9—21% of AF patients also
present diabetes mellitus [5,11,13,21,27,31,32]. Diabetes
mellitus was an independent risk factor for AF (odds ratio
1.4 [95% CI 1.0—2.0] in men and 1.6 [1.1—2.2] in women)
[1,2]. Obesity is also reported to carry a 50% higher risk
of AF in both men and women, mediated by left atrial
dilation [33].
Cigarette smoking has been identiﬁed as a signiﬁcant
age-adjusted risk factor in women [1,2]. A number of
non-cardiovascular factors have also been reported to trig-
ger acute, temporary AF, including alcohol intoxication
(so-called ‘holiday heart syndrome’), cardiac or thoracic
surgery, electrocution, myocardial infarction, pericarditis,
myocarditis, pulmonary embolism and other pulmonary dis-
orders, hyperthyroidism or other metabolic disorders and
severe infections [10].
Complications and prognosis of atrial
ﬁbrillation
Morbidity and atrial ﬁbrillation
The major complication associated with AF is stroke. It is
estimated that one of every six strokes occurs in AF patients
b
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C
A
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3] and that approximately 5% of patients with persistent or
ermanent AF each year will have a stroke [10].
The CHADS2 index is now used to determine the yearly
hromboembolic risk of AF patients, according to presence
r absence of the following risk factors: CHF (1 point),
ypertension (1 point), age > 75 years (1 point), diabetes (1
oint), history of stroke or transitory ischaemic attack (2
oints) [34]. The predictive value of this scoring system was
valuated in 1733 elderly patients with nonvalvular atrial
brillation, aged 65—95 years, who were not given warfarin
t hospital discharge. The risk of stroke increased from 1.9
n AF patient with a CHADS2 score of 0 to 18.2 in AF patients
ith CHADS2 score of 6 [35]. These ﬁgures have been vali-
ated by Rietbrock et al. in more than 50,000 AF patients
rom the General Practice Research Database in the UK [36].
The risk of ischaemic stroke has been reported to be
—7-fold higher in patients with non-rheumatic AF than in
atients without AF after adjustment for other factors and in
he absence of anticoagulant treatment [3,10]. Patients with
symptomatic AF have less severe heart disease, but seem
o have more frequent strokes or transient ischaemic attacks
han symptomatic patients (17% vs 13%, P = 0.005) [27].
The proportion of strokes attributable to AF increases
ith age [20]. In the Framingham Heart study, the annual
ncidence of stroke due to AF was 23.5% in patients aged
0—89 years, compared with only 1.5% in patients aged < 59
ears [20]. In patients with rheumatic heart disease and
F, the stroke risk increased 17-fold compared with age-
atched controls. The attributable risk was ﬁve-fold greater
han in those with non-rheumatic AF [37]. The risk of stroke
s higher in AF patients with predisposing factors such as a
revious history of stroke, arterial hypertension, coronary
rtery disease, myocardial infarction, diabetes and recent
eart failure. Combining the results of several studies, Hart
t al. highlighted four consistent risk factors for stroke in
atients with nonvalvular AF: increasing age, hypertension,
iabetes, and previous stroke or transient ischaemic acci-
ent, which is the most powerful risk factor, associated with
igh rates of stroke (10% per year on average) [38].
The risk of distal embolic events is also higher in patients
ith AF [39]. Authors of the ALFA study reported a 2.4%
ncrease in the incidence of emboli in subjects with AF, over
mean follow-up period of 8.6 months [13]. AF has also
een reported to increase the risk of evolution towards CHF
relative risk 2.98) [3].
eart failure
study in a community-based cohort in Minnesota showed an
ncidence of CHF of 7.8% within the ﬁrst 12 months after AF
iagnosis and of around 3% per year in the following years,
ith a cumulative CHF rate of 20% at 5 years [40]. In this
tudy, CHF in AF patients was associated with an increased
ortality risk of 3.4 [95% CI 3.1—3.8]. A higher risk of mortal-
ty has also been observed by Nieuwlaat et al. in AF patients
ith heart failure: 9.5% vs 3.3% after a 1-year follow-up
eriod [41]. Wang et al. studied the relationship between
F and heart failure, particularly the temporal relationship
etween the two conditions, in the Framingham cohort [42].
uring the study period, 1470 participants developed AF,
HF or both. Among patients with both conditions, 38% had
F ﬁrst, 41% had CHF ﬁrst and 21% had both diagnosed on
he same day. The incidence of CHF among AF subjects was
120
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Table 3 Common comorbidities in patients with atrial ﬁbrillation.
Study [reference]
ATRIA [5] AFFIRM [27] AFFIRM [31] WBAFP [21] Sudlow [32] ALFA [13] COCAF [11]
Country USA USA USA Canada UK UK France France
Category Asympt. Sympt.
Mean age (years) 71.2 70 69.7 69.7 70 76.6 ≥ 75 65—74 68.6 69.0
Eligibility > 65 years of age or at least one
risk factor
Paroxystic
or
persistent
AF, > 50
years
ECG AF in
patients
aged > 65
years
AF patients
of 206
cardiologists
AF patients
of 82
cardiologists
Sample size 17,974 481 3576 3400 660 111 160 47 756 671
Hypertension (%) 49.3 68 71 51 48 36.9 55.6 57.4 39.4 43
CAD (%) 34.6 28 40 26 25 28.8 — — 16.6 13
Cardiomyopathy
(%)
— 6.0 9.0 5 3 5.4 — — 15.3 —
Heart failure (%) 29.2 13 24 24 18 — 8.8 6.4 14.3 16
Valvular disease
(%)
4.9 12 12 5 6 26.1 22.5 10.6 18.5 13
Diabetes mellitus
(%)
17.1 21 20 20 18 — 9.4 12.8 10.7 —
Ischaemic
stroke/TIA (%)
8.9 17 13 — — — — — 8.4 —
Asympt: asymptomatic; CAD: coronary artery disease; ECG: electrocardiogram; Sympt.: symptomatic; TIA: transient ischaemic attack; WBAFP: West Birmingham Atrial Fibrillation Project.
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33 per 1000 person-years, and the incidence of AF among
CHF subjects was 54 per 1000 person-years. Development of
the other condition in patients with AF or CHF is associated
with a poor prognosis.
Atrial ﬁbrillation and quality of life
AF leading to reduced functional capacity, dyspnoea, pal-
pitations, fatigue, tachycardia-induced cardiomyopathy,
heart failure or angina signiﬁcantly affects quality of life
[43]. Even subjects with paroxysmal AF reported a substan-
tially worse quality of life than healthy control subjects,
using validated quality of life questionnaires [44].
Mortality and atrial ﬁbrillation: international data
Data on the contribution of AF to mortality are conﬂicting,
particularly in patients with mild-to-moderate heart fail-
ure. One study showed no increase in mortality in patients
with concomitant AF [45], whereas in another study, mor-
tality was signiﬁcantly higher in patients with AF than in
those with normal sinus rhythm (34% vs 23% respectively,
P < 0.001) [46]. In most studies, the increased mortality seen
in patients with AF has been linked to the severity of the
underlying heart disease rather than to the presence of AF
itself [1,3,27,45,46]. In some studies, AF does nevertheless
appear to contribute directly to increased mortality. In the
Manitoba follow-up study, AF increased the total mortality
risk 1.31-fold (P < 0.05) and increased the risk of cardio-
vascular mortality 1.41-fold. AF also increased the risk of
fatal stroke 2.48-fold [95% CI 1.35—4.57] [3]. After adjust-
ment for age, AF was associated with an overmortality of
2.4 in men and 3.5 in women. After adjustment for other
coexisting cardiovascular conditions and risk factors, AF was
associated with a 1.5-fold [1.2—1.8] higher risk of death in
men and 1.9-fold [1.5—2.2] increased risk in women, over all
age ranges [2].
In Sweden, a recent study of 888 patients treated for
paroxysmal AF at the hospital in Stockholm showed a mean
annual mortality rate of 7%, which corresponds to a stan-
dardized mortality ratio of 1.6 for all-cause mortality,
compared with the general population [47].
No association has been found between AF and non-
cardiovascular mortality in either men or women [29].
Atrial ﬁbrillation mortality in France
Although the hazard risk of stroke-related mortality was 2.0
[0.7—4.3] in men and 4.5 [1.3—16] in women in a French
population study, the risk of death among men without car-
diopathy or hypertension, after adjustment for other risk
factors, was not signiﬁcantly increased (overall mortality
1.1 [0.5—2.0], cardiovascular mortality 1.4 [0.6—2.9]) [12].
Furthermore, in the ALFA study, two-thirds of the 3.7% mor-
tality over 8.6 months was due to underlying cardiovascular
causes [13].
Data from CepiDC-IFR 69-INSERM on the medical causes
of death in French subjects [48] indicate that the annual
number of deaths from AF increased between 2000 and 2007,
particularly in older subjects (Fig. 2). A total of 3440 French
subjects (1183 men and 2257 women) died from AF in 2000
and 4747 (1678 men, 3069 women) died in 2007, but these
data are probably underestimated because they depend on
the details listed on death certiﬁcates. The age- and sex-
0
a
6
pigure 2. Mortality (per 100,000 persons) from atrial ﬁbrillation
etween 2000 and 2007 in France, according to age group, in (A)
en and (B) women.
tandardized mortality rate increased from 6.1 to 9.5 per
00,000 between 2000 and 2007.
ospitalizations
pproximately one-third of hospital admissions for cardiac
hythm disturbances are due to AF. In patients in the west of
cotland, Stewart et al. reported a rate of incident hospital-
zation of 1.9 cases/1000 person-years in the 20 years after
nitial screening for their study [23]. The number of hospital
dmissions for AF has increased by 66% over the last 20 years
ue to the ageing population, the increasing prevalence of
hronic heart disease and more frequent diagnosis [10]. In
he USA, the number of hospitalizations with AF as the pri-
ary diagnosis increased by 34% over the 6 years between
996 and 2001 [49].
In France, the 2008 PMSI database showed that around
4,000 patients were hospitalized with a principal diagno-
is of AF and 349,000 with an associated diagnosis of AF
total of 412,000 patients corresponding to 610,198 hospital
tays, 53.3% male). The number of cases increased regularly
ver the 3 years (+ 26% for the number of patients, + 32%
or the number of hospitalizations) (Fig. 3). Most of these
atients (92%) were aged ≥ 60 years. Major comorbidities
ere hypertension, heart disease, heart failure, stroke, syn-
ope and collapse, and dialysis (Table 4). In patients with
F as the principal diagnosis, the attributable mortality was
.6%; however, in patients who were hospitalized with AF
ssociated with another pathology, the mortality rate was
.6%, giving an overall hospital mortality of 5.6%.
In the Cost of Care in AF (COCAF) study, 31.3% of 671
atients with AF recruited by cardiologists across France
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figure 3. Number of AF patients hospitalized and total number o
ere hospitalized because of their disease [11]. Subjects
ith persistent or permanent AF were signiﬁcantly more
ikely to be hospitalized or to die compared with those
ith paroxysmal AF (P < 0.05, P < 0.001, respectively). In
his study, the ﬁnancial burden of AF was related to hos-
italization (52%), drugs (23%), consultations (9%), further
nvestigations (8%), loss of work (6%) and paramedic proce-
ures (2%).erspectives
he prevalence of AF in France is estimated at between
00,000 and 1 million patients, of which 400,000—660,000
p
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Table 4 Characteristics of patients hospitalized with atrial ﬁ
Principal diagnosis
Number of patients (n) 84,603
Men/women (%) 57.7/42.3
Age group (%)
< 40 years 2.6
40—44 years 1.6
45—49 years 2.8
50—59 years 12.5
60—69 years 20.6
70—79 years 31.4
≥ 80 years 28.3
Comorbidities (%)
Hypertension (I10 to I15) 33.9
Heart disease (I20 to I2298) 2.2
Heart failure (I50) 9.1
Stroke (I60 to I669) 1.2
Aortic stenosis —
Syncope and collapse (R55) —
Dialysis (Z491) —
Hospital deaths (%) 0.6pitalization stays for AF patients in France, 2005—2008.
re aged > 75 years. The number of new cases is
10,000—230,000 per year.
The number of patients with AF is increasing every year
nd the socioeconomic burden of AF is expected to continue
o increase in the foreseeable future.
An estimate of the projected number of AF patients
n France in 2050, based on central projected population
rends (70 million inhabitants; life expectancy 86.4 years;
eproduction rate 1.9; migration + 100,000 per year) and
ormer AF rates, has been calculated. With all reserves,
articularly due to the evolution of cardiovascular diseases
nd other risk factors in the population, it is estimated that
etween 1.1 and 2 million French people will present AF by
050.
brillation in France in 2008.
Associated diagnosis Total
348,683 412,047
52.4/47.6 53.3/46.7
0.4 0.8
0.3 0.6
0.7 1.1
4.4 5.8
11.3 12.9
30.4 30.4
52.4 48.4
— —
— —
15.0 —
0.8 —
1.0 —
1.1 —
2.9 —
6.6 5.6
i
S
F
e
I
i
p
R
[
[
[
[Epidemiology of atrial ﬁbrillation in France
Conclusion
This study focuses on the major published studies on the
incidence and prevalence of AF, and highlights the disparity
of approaches in terms of reference population studied and
deﬁnition of AF. These studies do not yet take into account
the recent recommendations of the European Society of Car-
diology with respect to the classiﬁcation of AF or the use of
different risk scores, including the CHA2DS2-VASc score.
The prevalence of AF in France is estimated to be
between 600,000 and 1 million people and the incidence
between 110,000 and 230,000 new cases per year. In 2008,
412,000 hospitalized patients had a diagnosis of AF, which
represents an increase of 26% over the 3 years from 2005
and 2008.
These ﬁgures emphasize the importance of targeting
therapy, of upstream therapy and of therapy that provides
clinical and economic advantages over the well-established
reductions already achieved in AF morbidity, mortality and
cost.
These perspectives have great implications for primary
prevention of cardiovascular diseases in young people and
screening for cardiovascular risk factors in adults (cardio-
vascular history, smoking status, systolic blood pressure,
cholesterol status, diabetes). The development of a scor-
ing system to predict an individual’s risk of developing AF
may contribute to its prevention [50].
New prevention strategies should be developed, par-
ticularly secondary prevention strategies in patients with
cardiovascular diseases.
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